New pill aims to calm stubborn hives
NCT ID NCT06865651
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests a new drug called remibrutinib for adults with chronic hives (urticaria) that are not well controlled by standard antihistamines. About 44 participants will receive either the drug or a placebo for 12 weeks. The goal is to see if the drug reduces itching, pain, and burning, and improves overall hive control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC URTICARIA (CU): CHRONIC INDUCIBLE URTICARIA (CINDU) AND CHRONIC SPONTANEOUS URTICARIA (CSU) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Endeavor Health
RECRUITINGGlenview, Illinois, 60077, United States
Contact Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGGrenoble, 38043, France
-
Novartis Investigative Site
RECRUITINGMontpellier, 34295, France
-
Novartis Investigative Site
RECRUITINGParis, 75970, France
-
Novartis Investigative Site
RECRUITINGPierre-Bénite, 69495, France
-
Novartis Investigative Site
RECRUITINGDresden, Saxony, 01307, Germany
-
Novartis Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Novartis Investigative Site
WITHDRAWNMainz, 55131, Germany
-
Novartis Investigative Site
RECRUITINGTübingen, 72076, Germany
-
Novartis Investigative Site
RECRUITINGPoznan, 61-731, Poland
-
Novartis Investigative Site
RECRUITINGRzeszów, 35 055, Poland
-
Novartis Investigative Site
RECRUITINGWarsaw, 02-962, Poland
-
Novartis Investigative Site
RECRUITINGBarcelona, Catalonia, 08003, Spain
-
Novartis Investigative Site
RECRUITINGPamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
RECRUITINGAlicante, 03010, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28006, Spain
-
Ziaderm Research LLC
RECRUITINGNorth Miami Beach, Florida, 33162, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.